What is Alzheimer’s, how common is it – and will new drug lecanemab help patients in the UK?

A new drug is making headlines around the world for being the first ever to slow the progression of Alzheimer’s disease.

After an 18-month trial of 1,800 patients, lecanemab slowed patients’ mental decline by 27%.

Although scientists are hailing a “new era” in treatment, strains on the NHS and the scale and complexity of the disease mean it
Read more…

Please follow and like us: